News und Analysen

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today reported

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and

Agilent Technologies Inc. (NYSE: A) today announced the company was again named one of the Most JUST Companies in America by Just Capital and CNBC. This marks the sixth year Agilent has appeared on

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today provided additional

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCA-Lung1) Phase II trial (PUMA-ALI-4201; NCT06095505) of alisertib

PINC AI™ Applied Sciences (PAS), a division of Premier, Inc. (NASDAQ: PINC), and Datavant, the company that protects, connects and delivers the world’s health data, announce the companies are

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced important U.S. and European regulatory updates for isaralgagene civaparvovec, or ST-920, its wholly owned gene

Owens & Minor, Inc. (NYSE: OMI) plans to release financial results for the fourth quarter of 2023 on Tuesday, February 20, 2024, before trading begins on the New York Stock Exchange.

The Company

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2023.

Fourth Quarter 2023 Financial Highlights:

• 
  Revenue grew 27%

Agilent Technologies Inc. (NYSE: A) announced today that it has received two prestigious awards from SelectScience: Best New Drug Discovery & Development Product of 2023 and Drug Discovery &amp

Agilent Technologies Inc. (NYSE: A) today announced that CFO Bob McMahon will participate in a fireside chat at the 44^th Annual TD Cowen Health Care Conference in Boston, Massachusetts, on Monday

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its fourth quarter and year-end 2023 results on Tuesday, February 27, 2024, after the close of the market. Acadia

Humana Inc. (NYSE: HUM), a leading U.S. health insurer and healthcare services company, continues to make strides in advancing health equity by releasing the findings of its new pilot study

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2023.

Highlights and Outlook

• 
  Q4 sales grew 14 percent to $1.53 billion; constant currency¹
  

Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today announced it

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it will participate in two

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary data from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or

Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal-year 2024 second quarter ended December 31, 2023.

"Our

Premier, Inc. (NASDAQ: PINC) (“Premier” or the “Company”), a leading technology-driven healthcare improvement company, today announced that the Company’s Board of Directors has concluded its

The American Cancer Society (ACS) and Pfizer Inc. (NYE: PFE) today announced the launch of “Change the Odds™: Uniting to Improve Cancer Outcomes,” a three-year initiative to bridge the gap in

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee.

On January 31

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will be participating at the following investor

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report fourth quarter and full year

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, and ClearNote Health, Inc., a pioneer in epigenomic technologies, today unveiled an alliance through which Personalis will

Agilent Technologies Inc. (NYSE: A) today announced an agreement with Incyte that will bring together Agilent’s expertise and proven track record in the development of companion diagnostics (CDx)